skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Acalabrutinib (Code C113442)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Acalabrutinib

Definition: An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

Display Name: Acalabrutinib

Label: Acalabrutinib

NCI Thesaurus Code: C113442 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C4078312  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Benzamide, 4-(8-Amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl-
Bruton Tyrosine Kinase Inhibitor ACP-196

External Source Codes: 
CAS Registry Number 1420477-60-6 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 756623
PDQ Open Trial Search ID 756623 (check for NCI PDQ open clinical trial info)
UMLS CUI C4078312

Other Properties:
     Name Value (qualifiers indented underneath)
code C113442
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom